Analysts at Liberum Capital Kept the Same their Buy rating for GlaxoSmithKline PLC (LON:GSK). The Target Price per Share Given is GBX 1760.00; Draper Oakwood Tech Acquisition (DOTA) SI Increased By 333.33%

Draper Oakwood Tech Acquisition (NASDAQ:DOTA) had an increase of 333.33% in short interest. DOTA’s SI was 2,600 shares in January as released by FINRA. Its up 333.33% from 600 shares previously. With 21,400 avg volume, 0 days are for Draper Oakwood Tech Acquisition (NASDAQ:DOTA)’s short sellers to cover DOTA’s short positions. The stock increased 0.41% or $0.04 during the last trading session, reaching $9.83. About 10,458 shares traded. Draper Oakwood Technology Acquisition, Inc. (NASDAQ:DOTA) has 0.00% since January 15, 2017 and is . It has underperformed by 16.70% the S&P500.

In a report revealed to clients and investors on today, Liberum Capital reaffirmed their Buy rating on GlaxoSmithKline PLC (LON:GSK)‘s stock. The target price per share indicates a potential upside of 30.27% from firm’s last stock close.

Draper Oakwood Technology Acquisition, Inc. intends to acquire businesses or assets through merger, capital stock exchange, stock purchase, reorganization, recapitalization, exchangeable share transaction, or other business transaction. The company has market cap of $22.33 million.

The stock decreased 0.52% or GBX 7 during the last trading session, reaching GBX 1346. About 1.46 million shares traded. GlaxoSmithKline plc (LON:GSK) has 0.00% since January 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 28 analysts covering GlaxoSmithKline PLC (LON:GSK), 8 have Buy rating, 4 Sell and 16 Hold. Therefore 29% are positive. GlaxoSmithKline PLC has GBX 2000 highest and GBX 1075 lowest target. GBX 1560.58’s average target is 15.94% above currents GBX 1346 stock price. GlaxoSmithKline PLC had 418 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by Credit Suisse on Thursday, February 9 with “Neutral”. JP Morgan maintained the shares of GSK in report on Monday, July 24 with “Neutral” rating. The stock has “Hold” rating by Jefferies on Thursday, September 10. As per Tuesday, January 19, the company rating was maintained by Barclays Capital. BNP Paribas maintained GlaxoSmithKline plc (LON:GSK) rating on Monday, December 7. BNP Paribas has “Neutral” rating and GBX 1400 target. HSBC maintained GlaxoSmithKline plc (LON:GSK) on Wednesday, November 22 with “Buy” rating. UBS maintained the stock with “Neutral” rating in Tuesday, December 13 report. Jefferies maintained GlaxoSmithKline plc (LON:GSK) rating on Friday, February 17. Jefferies has “Buy” rating and GBX 1800 target. Helvea maintained it with “Hold” rating and GBX 1530 target in Friday, February 12 report. Berenberg maintained GlaxoSmithKline plc (LON:GSK) rating on Wednesday, July 26. Berenberg has “Buy” rating and GBX 1885 target.

Analysts await GlaxoSmithKline plc (LON:GSK) to report earnings on February, 14. They expect $0.64 EPS, down 1.54% or $0.01 from last year’s $0.65 per share. GSK’s profit will be $31.08M for 525.78 P/E if the $0.64 EPS becomes a reality. After $0.85 actual EPS reported by GlaxoSmithKline plc for the previous quarter, Wall Street now forecasts -24.71% negative EPS growth.